Your browser doesn't support javascript.
loading
Protein Phosphatase Magnesium-Dependent 1δ (PPM1D) Expression as a Prognostic Marker in Adult Supratentorial Diffuse Astrocytic and Oligodendroglial Tumors.
Jeong, Hui Jeong; Woo, Chang Gok; Lee, Bora; Khang, Shin Kwang; Nam, Soo Jeong; Choi, Jene.
Afiliação
  • Jeong HJ; Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Woo CG; Department of Pathology, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, Korea.
  • Lee B; Department of Biostatistics, Clinical Trial Center, Soonchunhyang Medical Center, Bucheon, Korea.
  • Khang SK; Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Nam SJ; Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Choi J; Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
J Pathol Transl Med ; 52(2): 71-78, 2018 Mar.
Article em En | MEDLINE | ID: mdl-29046514
ABSTRACT

BACKGROUND:

Protein phosphatase magnesium-dependent 1δ (PPM1D) is a p53-induced serine/threonine phosphatase, which is overexpressed in various human cancers. A recent study reported that a mutation in the PPM1D gene is associated with poor prognosis in brainstem gliomas. In this study, we evaluated the utility of PPM1D as a prognostic biomarker of adult supratentorial diffuse astrocytic and oligodendroglial tumors.

METHODS:

To investigate PPM1D protein expression, mRNA expression, and copy number changes, immunohistochemistry, RNAscope in situ hybridization, and fluorescence in situ hybridization were performed in 84 adult supratentorial diffuse gliomas. We further analyzed clinical characteristics and overall survival (OS) according to PPM1D protein expression, and examined its correlation with other glioma biomarkers such as isocitrate dehydrogenase (IDH) mutation, and p53 expression.

RESULTS:

Forty-six cases (54.8%) were PPM1D-positive. PPM1D expression levels were significantly correlated with PPM1D transcript levels (p= .035), but marginally with PPM1D gene amplification (p=.079). Patients with high-grade gliomas showed a higher frequency of PPM1D expression than those with low-grade gliomas (p <.001). Multivariate analysis demonstrated that PPM1D expression (hazard ratio [HR], 2.58; p=.032), age over 60 years (HR, 2.55; p=.018), and IDH1 mutation (HR, 0.18; p=.002) were significantly independent prognostic factors; p53 expression had no prognostic significance (p=.986). The patients with tumor expressing PPM1D showed a shorter OS (p=.003). Moreover, patients with tumor harboring wild-type IDH1 and PPM1D expression had the worst OS (p<.001).

CONCLUSIONS:

Our data suggest that a subset of gliomas express PPM1D; PPM1D expression is a significant marker of poor prognosis in adult supratentorial diffuse astrocytic and oligodendroglial tumors.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: J Pathol Transl Med Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: J Pathol Transl Med Ano de publicação: 2018 Tipo de documento: Article